Skip to content

Effect of closed-loop acoustic stimulation on improving sleep structure and inflammatory response in patients with major depressive disorder

Effect of closed-loop acoustic stimulation on improving sleep structure and inflammatory response in patients with major depressive disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096773
Enrollment
Unknown
Registered
2025-02-06
Start date
2025-07-07
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

CLAS group:Simultaneously with sleep EEG monitoring, 2-week CLAS intervention during sleep will be conducted
Sham group:Only conducting 2-week sleep EEG monitoring without intervention of CLAS during sleep

Sponsors

Hangzhou Seventh People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Outpatient or inpatient patients aged 18-50 (including 18 and 50 years old), regardless of gender; (2) Right-handed, primary school education or above; (3) Meets the diagnostic criteria for major depressive disorder episodes in DSM-5, single episode or recurrent episode; (4) Hamilton Depression Rating Scale (HAMD-24) score >= 20 points; (5) Pittsburgh Sleep Quality Index (PSQI) score >= 5; (6) No antidepressant drugs were used or the current antidepressant treatment plan was stably used for at least 4 weeks; (7) Understand and voluntarily participate in this study, be able to follow the treatment process, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Meet the diagnostic criteria for other mental disorders in DSM-5, such as post-traumatic stress disorder, neurocognitive disorders, schizophrenia, bipolar disorder, alcohol (or drug) dependence or abuse, personality disorders, etc; (2) Depressive episodes secondary to a systemic or neurological disorder; (3) Serious physical illnesses, such as heart, liver, and kidney dysfunction, impaired respiratory function, severe infections, etc; (4) Any serious neurological disease or damage, including but not limited to space occupying brain injury, history of epileptic seizures, Parkinson's disease, multiple sclerosis, severe head trauma; (5) Implanting electronic devices such as pacemakers and cochlear implants into the body; (6) Pregnant or lactating patients; (7) Received other neuroregulatory treatments such as MECT or rTMS within the past 3 months; (8) Individuals with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, or with upper respiratory tract infections or other infectious diseases within 2 weeks prior to enrollment; (9) HAMD-24 score >= 3 in item 3, or those who currently or in the past 12 months have a clear tendency towards suicide, and are considered at risk of suicide and violent behavior based on the researcher's clinical assessment.

Design outcomes

Primary

MeasureTime frame
Sleep architecture;Inflammatory indicators;Depressive degree;

Secondary

MeasureTime frame
Anxiety degree;Depressive symptoms;Anxiety symptoms;Suicidal ideation;Clinical symptoms;Sleep quality;Sleep rhythm;Brain function;Heart rate variability;Cognitive function;Sex hormone;

Countries

China

Contacts

Public ContactDeng Wei

Hangzhou Seventh People's Hospital

dengw@zju.edu.cn+86 134 8403 6877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026